LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the Stifel 2020 Virtual Healthcare Conference on November 17 at 10:40 a.m. ET. The live discussion will be accessible via a webcast on the company's Investors section of their website. A replay will be available for 90 days following the event. LivaNova, headquartered in London, focuses on innovative medical technologies across two business sectors: Cardiovascular and Neuromodulation, serving over 100 countries worldwide.
LivaNova PLC (NASDAQ: LIVN) reported third-quarter 2020 results with worldwide sales of $240.1 million, a decline of 10.6% year-over-year. Adjusted diluted earnings per share were $0.38, down from $0.84 in the same quarter last year. The company faced revenue decline due to COVID-19, particularly affecting Cardiopulmonary and Neuromodulation segments. However, Advanced Circulatory Support saw a significant increase of 91.9%. LivaNova's guidance expects a full-year net sales decline of 7-17% on a constant-currency basis.
LivaNova PLC (NASDAQ:LIVN) has acknowledged a letter from PrimeStone Capital LLP, expressing openness to constructive dialogue aimed at enhancing shareholder value. The Company’s leadership has engaged in discussions with PrimeStone over the last few months, reaffirming its commitment to executing its strategic plan and improving patient outcomes through innovative medical technologies. An update on Company performance is scheduled for the third quarter earnings call on October 29, 2020.
LivaNova PLC (NASDAQ:LIVN) announced promising results from the PERSIST-AVR and SURE-AVR studies at the 34th Annual Meeting of the EACTS. The PERSIST-AVR study, involving 910 patients, demonstrated that the Perceval sutureless valve, when used in minimally invasive cardiac surgery, resulted in significantly lower major adverse cardiovascular events (5.2% vs. 10.8% for stented valves) and reduced stroke rates (1% vs. 5.4%). Additionally, SURE-AVR results showed comparable performance between Perceval via minimally invasive techniques and traditional approaches. These findings bolster the case for Perceval's role in innovative heart valve solutions.
LivaNova PLC (NASDAQ:LIVN) will host a conference call on October 29, 2020, at 12 p.m. London time to discuss its third-quarter 2020 results, releasing the results prior to the call. The audiocast will be available in the Investor Relations section of LivaNova's website, with listeners advised to log on 10 minutes early. For telephone participation, dial 844-239-5285 (U.S.) or 512-961-6524 (international), using conference ID 1897870. A replay will be accessible for 90 days post-call. LivaNova operates in Cardiovascular and Neuromodulation sectors, serving over 100 countries.